February 23, 2021

#### Nifty Outlook

Markets started the week on a feeble note and lost over 2%, tracking subdued global cues. Among the benchmark indices, the Nifty index slipped below the crucial support zone of 14,800 and finally closed at 14,676 levels. Mostly sectoral indices, except metal, ended with losses wherein realty, auto and IT were the top losers. The broader market indices too witnessed sell-off as both midcap and smallcap ended with losses of more than 1%.

The recent spike in the COVID cases combined with subdued global cues is weighing on the sentiment. After this slide, Nifty has lost momentum and the next major support exists at 14,300. In the case of a rebound, the 14,850 zone would act as a hurdle. Going ahead, macroeconomic data i.e. GDP data and core sector data and updates on COVID-19 cases would be actively tracked.

	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	14450	15000	14000
News			

- L&T announced that its Power Transmission and Distribution business has won a slew of
  orders across its spectrum of offerings.
- **Torrent Power** emerged as the highest Bidder for the sale of 51% stake in the Power Distribution Company in the UT of Dadra & Nagar Haveli and Daman & Diu.
- **Dr. Reddy's Laboratories** announced the launch of Lansoprazole DR Orally Disintegrating Tablets a therapeutic equivalent generic version of Prevacid SoluTab DelayedRelease Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the USFDA.



# Religare Super Idea\*\* Scrip Buy/Sell CMP Initiation Range SL\* Target HCLTECH BUY 900 PE (MAR) 30.90 22-26 16 45

\*\*Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

\*Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

Derivative Ideas **				Sectors to watch		FII & DII Cash Segment (Rs. in Cr.)			Trade Stats					
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET	Sector Name	Outlook	Category	Amt.	MTD	FYTD		NO OF CONTRACTS	TURNOVER IN CR
						п	BULLISH	FII**	119	23875	182401	IDXFUTS	487401	48043
	BUY 470									23073	102101	IDXOPT	30145546	18202
ICICIPRULI	PE (FEB)	1500	6-7	1	15	BANKS	STABLE	DII**	-1175	-16638	-137028	STKFUTS	1620635	144638
						FMCG	STABLE	**Provisio	nal data	as on 19 <sup>th</sup>	February, 20	021		



February 23, 2021



#### **Derivative Ideas**

**ICICIPRULI** added around 14% in open interest addition as SHORT buildup was seen in it in till closing time. Current chart pattern also indicates further down move in its price. We suggest buying ICICIPRULI 470 PE as per below levels.

#### Strategy:- BUY ICICIPRULI 470 PE AT 6-7 STOPLOSS AT 1 TARGET 15.

Investment Pick - Britannia Industries Ltd.									
Scrip CMP Recommendation Price Target Duration									
Britannia Industries Ltd.	3,341.2	3,462	4,265	9-12 Months					

Britannia Industries (BRIT) posted mixed numbers wherein revenue was below our expectation while profit grew strong. Revenue came in at Rs 3165.6cr, up by 6.1% YoY. On operational front, its EBITDA grew by 21.7% YoY to Rs 611.5cr, while margin expanded by 248bps on the back of cost efficiencies measures. The company reported healthy growth of 22.4% YoY in net profit at Rs 452.6cr with margin expansion of 190bps YoY to 14.3%. Going forward, we remain positive on the company's long term growth as the focus would be enhancing sales, improving margins via cost efficiency measures and strengthening distribution reach. Maintain a Buy.

Going forward, BRIT strategy would be to drive strong growth by launching new and innovating products, focus on brand building and strengthening distribution reach. Besides its efforts on improving margins via cost efficiency would be its core agenda. Apart from this, strong growth momentum from rural and international businesses will continue to support and lead to market share gains. Further along with the optimistic management plan the company has strong balance and decent cash flow which would aid growth. Thus, we have a positive view on the stock for long term and have maintained a buy rating on the stock with a target price of Rs 4,265.

CACT Calendar -	CACT Calendar - February 2021 (Buy Back of Shares)										
Sun	Mon	Tue	Wed	Thu	Fri	Sat					
21	22	23	24	25	26	27					
		• Niit Ltd.		• Gujarat Apollo Industries Ltd.	• Smartlink Holdings Ltd.						

Eonomic Calendar - February 2021											
Sun	Mon	Tue	Wed	Thu	Fri	Sat					
21	22	23	24	25	<ul> <li>Federal Fiscal Deficit (Jan)</li> <li>GDP Annual</li> <li>GDP Quarterly (YoY) (Q3)</li> <li>Infrastructure Output (YoY) (Jan)</li> </ul>	27					

February 23, 2021



CACT Color		2024 /6-	sh Dividend)
I ( A ( I ( alen	idar - Februai	V 2021 IC a	ish Dividendi

Su	Mon	Tue	Wed	Thu	Fri	Sat
21	<ul> <li>Aurobindo Pharma Ltd.</li> <li>Dcm Shriram Industries Ltd.</li> <li>Goldiam International Ltd.</li> <li>Itc Ltd.</li> <li>Mazagon Dock Shipbuilders Ltd</li> <li>Mercury Laboratories Ltd</li> <li>Natco Pharma Ltd.</li> <li>Nhpc Ltd.</li> <li>Panchsheel Organics Ltd.</li> <li>Selan Exploration Technology Ltd.</li> <li>Shanthi Gears Ltd.</li> <li>Tube Investments Of India Ltd</li> </ul>	<ul> <li>23</li> <li>Cochin Shipyard Ltd</li> <li>Ircon International Ltd</li> <li>Oil India Ltd.</li> <li>Precision Wires India Ltd.</li> <li>Sjvn Ltd</li> <li>Tower Infrastructure Trust</li> <li>United Drilling Tools Ltd.</li> <li>Zuari Global Ltd.</li> </ul>	<ul> <li>24</li> <li>Isgec Heavy Engineering Ltd</li> <li>Karda Constructions Ltd</li> <li>Nile Ltd.</li> <li>Racl Geartech Ltd</li> <li>Sandhar Technologies Ltd</li> <li>Techno Electric &amp; Engineering Company Ltd</li> </ul>	<ul> <li>25</li> <li>Amara Raja Batteries Ltd.</li> <li>Career Point Ltd.</li> <li>Dharamsi Morarji Chemical Co.Ltd.</li> <li>G M Polyplast Ltd</li> <li>The Yamuna Syndicate Ltd</li> </ul>	26	27

#### CACT Calendar - February 2021 (Right Issue of Equity Shares) Wed Thu Fri Sun Mon Tue Sat 24 21 22 25 26 23 27 Arvind Fashions Ltd • •

CACT C	CACT Calendar - February 2021 (Bonus Issue 5:8)									
Sun	Mon	Tue	Wed	Thu	Fri	Sat				
21	22	23	24	25	26	27				
				Nakoda Group Of Industries Ltd						

## Result Calendar - February 2021

Sun	Mon	Tue	Wed	Thu	Fri	Sat
<ul> <li>21</li> <li>India Finsec Ltd.</li> <li>Uniply Decor Ltd</li> <li>Uniply Industries Ltd.</li> </ul>	22 • Apoorva Leasing Fi- nance And Investment Company Ltd	<ul><li>23</li><li>Elantas Beck India Ltd.</li><li>Sanofi India Ltd</li></ul>	24	<ul> <li>25</li> <li>Ksb Ltd</li> <li>Rain Industries Ltd</li> <li>Vesuvius India Ltd.</li> </ul>	<ul> <li>Alliance Integrated Metaliks Ltd.</li> <li>Abb Power Products And Systems India Ltd</li> <li>Stovec Industries Ltd.</li> </ul>	27

February 23, 2021

#### Religare Investment Calls



Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %		
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	484	27.8%		
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	305	23.1%		
Godrej Consumer Products	16-Sept-2020	Buy	Investment Call	706	845	19.7%	699	20.8%		
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas / Diwali Picks	450	709	57.6%	570	24.3%		
Sudarshan Chemical Industries	09-Nov-2020	Buy	Diwali Picks	442	583	31.9%	500	16.6%		
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	756	29.4%		
JK Lakshmi Cement	28-Dec-2020	Buy	New Year Picks 2021	337	428	27.0%	366	16.8%		
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	167	22.5%		
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	795	42.8%		
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	849	25.9%		
Dabur India	04-Feb-2021	Buy	High Conviction Ideas	525	616	17.3%	500	23.1%		
Castrol India	09-Feb-2021	Buy	Investment Call	134	148	10.4%	126	17.6%		
Britannia Industries	10-Feb-2021	Buy	High Conviction Ideas	3,462	4,265	23.2%	3,341	27.6%		

\*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

Hold - Potential Returns <10% over 12 months

For Religare Investment calls performance <u>click here</u>

February 23, 2021

#### Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

		For 1L m	nargin*						
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call			
Intraday Calls	Intraday	2 - 3	< 1 day	25%	25,000	8,000			
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%	30,000	4,000			
Master Pick	Weekly	1	1 month	15%	15,000	5,000			
Religare Alpha	Opportunity	NA	2 - 3 months	20%	20,000	As per weightage			
Cash		NA		10%	10,000				
Intraday Calls	These calls are flashed live on Ms Lync and ODIN with the purpose of squaring off positions on the same day. As a policy, we restrict our intraday cash market calls to less than 4 calls a day. Hence, funds should be allocated accordingly to have provision to trade in all calls.								
Live / RMD Calls		lls). 3-4 such call	s are made on a daily basis	days. Additionally as per market opp which might be open for 3-4 days. Fun					
Master Pick	-			f techno-funda analysis. 15% of funds pen duration for this call will be 1 mon		llocated for Master			
Religare Alpha	•	This is a portfolio of 8-10 stocks which are held with a view of 2-3 months. It is recommended to allocate 20% of funds for building this portfolio which will provide stability to the overall trading portfolio.							
Cash	10% surplus cash i	n the portfolio s	hould be kept for the purpo	oses of allocating it to opportunities as	and when they arrive.				

		For derivative n	narket trading		For 1L ma	For 1L margin*			
Call / Product	Call Frequency	Frequency No. of calls Avg open call duration % funds allocated		Total	Per Call				
Derivative Ideas	Daily	1 - 2	1 - 3 days	40,000	40,000				
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000			
Cash		NA		10%	10,000				
Derivative Ideas			ı. It can be a plain vanilla F&O l e calls are open for 3-4 days on		egy. Funds should be allo	ocated assuming 2			
Live Calls	These calls are flashed on MS Lync and ODIN during live market hours. These calls can be intraday or with a view of 2-3 days. Funds should be allocated considering 2 such calls will be open at any time. 3/4 times, these calls will be on Nifty / Bank Nifty only.								
Cash	It is recommended to	o hold 10% cash to	capitalize on any opportunity t	hat may arise in markets.					



February 23, 2021



# Research Analysts

Ajit Mishra	ajit.mishra@religare.com		
Himanshu Sharma	himanshu.sharma1@religare.com		
Manoj M Vayalar	manoj.vayalar@religare.com		
Nirvi Ashar	nirvi.ashar@religare.com		
Rohit Khatri	rohit.khatri@religare.com		
Suhanee Shome	suhanee.shome@religare.com		

#### February 23, 2021



Before you use this research report , please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <a href="https://www.religareonline.com/disclaimer">https://www.religareonline.com/disclaimer</a>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest , compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below , are given separately]

S. No.	Statement	Ansv	wer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	

I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
I/we have received any compensation from the subject company in the past twelve months?			
I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	

	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?	No
	I/we have served as an officer, director or employee of the subject company?	No
	I/we have been engaged in market making activity for the subject company?	No

Nature of Interest ( if answer to F (a) above is Yes : .....

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above , are given below]

SSNo.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results